bioRxivCell BiologyPreprint
Nonmuscle myosin II shRNA inhibit migration and contraction in rat hepatic stellate cells through regulating AKT/mTOR/S6K/4EBP1 signaling pathway
Zhenghong Li, Yun Feng, Ruling Zhang, Peiwen Wang, Lungen Lu, Yuwei Dong
Abstract
Migration and contraction of activated hepatic stellate cell (HSC) are essential factors for cirrhosis formation and development. It has been demonstrated that blebbistatin, a nonmuscle myosin II (NMMII) inhibitor, can inhibit the migration and contraction of HSC, whereas the main cell signaling pathway is still unknown. Mammalian target of rapamycin (mTOR) signaling pathway may be involved in many cells migration and contraction, whether NMMII and mTOR have any crosslinks draw our attention. In the currently study, we used LV-RNAi to specifically attenuate mTOR and NMMII in rat HSC. We aimed to examine the effect of mTOR LV-RNAi on the migration and contraction of HSC and explore the crosslink between mTOR cell signal and NMMII. Using real-time PCR and western blot, we found that mTOR and the downstream factors including S6K and 4EBP1 all up-regulated with the activation of HSC, mTOR and NMMII LV-RNAi was transfected into activated HSC using lipofectamine 2000. The levels of mRNA and proteins were also examined using real-time PCR and western blot respectively. The expression of mTOR can be down-regulated by NMMII LV-RNAi significantly, as well as the expression of S6K, 4EBP1, -SMA and collagen I, but the level of AKT was up-regulated. Then we used Transwell system and collagen lattices to examine the NMMII and mTOR LV-RNAi efficiency on HSC migration and contraction, as we hypothesized, both of the LV-RNAi could inhibit HSC migration and contraction significantly. These results indicated that nonmuscle myosin II shRNA inhibit migration and contraction in rat hepatic stellate cells through the regulation of mTOR/S6K/4EBP1 signaling pathway
- organism: rat
- assay: bulk RNA-seq
- research focus: cell signaling & trafficking
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- IL-11 neutralising therapies target hepatic stellate cell-induced liver inflammation and fibrosis in NASH
Anissa Anindya Widjaja, Brijesh Kumar Singh, … Stuart A. Cook·GastroenterologyPeer-reviewed·May 9, 2019
- Nanchangmycin regulates FYN, FAK and ERK to control the fibrotic activity of hepatic stellate cells
W. Li, J. Y. Chen, … A. C. Mullen·bioRxiv·Oct 8, 2021
- Mitochondrial Pyruvate Carrier Inhibition Attenuates Hepatic Stellate Cell Activation and Liver Injury in a Mouse Model of Metabolic Dysfunction-associated Steatotic Liver Disease
M. Habibi, D. Ferguson, … B. N. Finck·bioRxiv·Feb 13, 2023
- Lactate transporter MCT1 in hepatic stellate cells promotes fibrotic collagen expression in nonalcoholic steatohepatitis
Kyounghee Min, Batuhan Yenilmez, … Michael Czech·eLifePeer-reviewed·Aug 31, 2023
- Inhibiting endoplasmic reticulum stress decreases tumor burden in a mouse model for hepatocellular carcinoma.
N. Pavlovic, C. Calitz, … F. Heindryckx·bioRxiv·Feb 20, 2020
- The ameliorative effect of C-Kit pos hepatic endothelial Mertk deficiency on nonalcoholic steatohepatitis
Sengwang Fu, Yu-Xuan Gao, … Mingyi Xu·bioRxiv·Aug 8, 2024